DEPLOY

Buying guide

Apple Watch vs Fitbit (Charge / Sense / Versa) in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Attribute
No image on file
Apple WatchView full model page →
Google product image of the Fitbit Charge 6 fitness tracker worn on the wrist. Its ECG and irregular-rhythm (AFib) notifications are FDA-cleared; activity and sleep scores are wellness-grade.
Fitbit (Charge / Sense / Versa)View full model page →
ManufacturerAppleFitbit
Form factorbiometricbiometric
Maturitycommercialcommercial
Availabilityshipping-nowshippingshipping-nowshipping
Price$399-$799 (actual sale price)$110-$160 (actual sale price)
Capability claims
  • Detects irregular heart rhythm (autonomous, verified)
  • Tracks heart health (autonomous, verified)
  • Tracks blood oxygen (SpO2) (claimed-only, claimed)
  • Tracks fitness and activity (autonomous, verified)
  • Tracks sleep (claimed-only, claimed)
  • Tracks sleep (autonomous, verified)
  • Tracks fitness and activity (autonomous, verified)
  • Tracks heart health (claimed-only, claimed)
Brain——
Verified deployments1Apple1Fitbit
Privacy practices13cloud-upload, third-party-sharing, location-tracking, on-device-processing, training-data-use, data-sale, data-retention, biometric-storage, data-deletion-control, data-sale, data-deletion-control, data-retention, biometric-storage13data-deletion-control, data-sale, cloud-upload, data-retention, location-tracking, training-data-use, biometric-storage, third-party-sharing, Other disclosed, biometric-storage, data-sale, data-deletion-control, data-retention
Sources on file2622

Editorial summaries

Apple Watch

The Apple Watch (current Series 11 and Ultra 3, September 2025; Series 9/10 and Ultra 2 supported) is a biometric-primary smartwatch and the canonical reference of the biometric cohort, with the broadest FDA-cleared portfolio: ECG and AFib/irregular-rhythm notifications (De Novo 2018), sleep-apnea notifications (2024), and hypertension notifications (2025), plus fall and crash detection and the Vitals app. Its sensors (optical PPG, electrical ECG, temperature, accelerometer/gyro, blood-oxygen) need no subscription for the FDA-cleared medical features. Pricing anchors at about $399 for the Series base (aluminum, GPS), with the Ultra around $799 and the SE around $249 (the SE lacks ECG). A within-entity verified-vs-claimed exemplar: blood-oxygen was disabled in the US in January 2024 over the Masimo ITC ruling and re-enabled in August 2025 via a paired-iPhone calculation redesign. DEPLOY holds the claims to the specific cleared indications: these are cleared features with defined scope, not a general cardiac or sleep diagnostic.

Fitbit (Charge / Sense / Versa)

Fitbit (the Charge 6 band, plus the Sense 2 and Versa 4 watches; founded 2007 by James Park and Eric Friedman, acquired by Google in a deal that closed January 2021 for about $2.1B) is the budget-tier cleared anchor of the biometric cohort. The Charge 6, at about $160, brings cleared AFib/ECG (via electrodes on the Sense line), optical heart rate, SpO2, skin temperature, a Sleep Score and Sleep Profile, a Daily Readiness Score, and stress management, with an optional Fitbit Premium subscription (~$9.99/month). It is a Google product line, recorded in the registry as a distinct entity from the Pixel Watch and the Google company, and its health stack shares lineage with the Pixel Watch's Fitbit/Google Health algorithms. The throughline: the strongest cardiologist-validation gradient available at a budget price point, with the AI augmenting genuine biometric sensing.

Machine-readable: this page as markdown.

← Back to all consumer robots